This Article Full Text Full Text (PDF) Supplementary Data All Versions of this Article: 0008-5472.CAN-08-0946v1 69/3/887    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ecke, I. Articles by Hahn, H. Search for Related Content PubMed PubMed Citation Articles by Ecke, I. Articles by Hahn, H.

Antitumor Effects of a Combined 5-Aza-2'Deoxycytidine and Valproic Acid Treatment on Rhabdomyosarcoma and Medulloblastoma in Ptch Mutant Mice

¹ Institute of Human Genetics, Departments of ² Genetic Epidemiology, ³ Pediatrics, ⁴ Diagnostic Radiology, ⁵ Molecular Oncology, ⁶ Pathology, and ⁷ Central Animal Facility, University of Goettingen, Göttingen, Germany; ⁸ Department of Pharmacology, University of Mainz, Mainz, Germany; and ⁹ Clinical Cooperation Unit Pediatric Oncology, DKFZ Heidelberg, and Department of Pediatric Oncology, Children's Hospital, University of Heidelberg, Heidelberg, Germany

Requests for reprints: Heidi Hahn, Institute of Human Genetics, University of Goettingen, Heinrich-Dueker Weg 12, 37073 Goettingen, Germany. Phone: 49-551-3914010; Fax: 49-551-396580; E-mail: hhahn{at}gwdg.de.

Key Words: patched • VPA • 5-aza-dC

Patched (Ptch) heterozygous mice develop medulloblastoma (MB) and rhabdomyosarcoma (RMS) resembling the corresponding human tumors. We have previously shown that epigenetic silencing of the intact Ptch allele contributes to tumor formation in this model. Here, we investigated whether targeting of epigenetic silencing mechanisms could be useful in the treatment of Ptch-associated cancers. A reduction of endogenous DNA methyltransferase1 (Dnmt1) activity significantly reduced tumor incidence in heterozygous Ptch knockout mice. A combined treatment with the Dnmt inhibitor 5-aza-2'deoxycytidine (5-aza-dC) and the histone deacetlyase (HDAC) inhibitor valproic acid (VPA) efficiently prevented MB and RMS formation, whereas monotherapies with either drug were less effective. Wild-type Ptch expression was efficiently reactivated in tumors by 5-aza-dC/VPA combination therapy. This was associated with reduced methylation of the Ptch promoter and induction of histone hyperacetylation suggesting inhibition of HDACs in vivo. However, the treatment was not effective in clinically overt, advanced stage tumors. This is a first in vivo demonstration that targeting of Dnmt and HDAC activities is highly effective in preventing formation of Ptch-associated tumors. The results suggest a novel clinical strategy for consolidation therapy of corresponding tumors in humans after completion of conventional treatment. Our data also suggest that epigenetic therapy may be less effective in treating advanced stages of tumors, at least in this tumor model. [Cancer Res 2009;69(3):887–95]

This article has been cited by other articles:

				A. Zibat, A. Uhmann, F. Nitzki, M. Wijgerde, A. Frommhold, T. Heller, V. Armstrong, L. Wojnowski, L. Quintanilla-Martinez, J. Reifenberger, et al. Time-point and dosage of gene inactivation determine the tumor spectrum in conditional Ptch knockouts Carcinogenesis, June 1, 2009; 30(6): 918 - 926. [Abstract] [Full Text] [PDF]